Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival

Valeria Sebastiani, Francesca Ricci, Belen Rubio-Viquiera, Piotr Kulesza, Charles J. Yeo, Manuel Hidalgo, Alison Klein, Daniel Laheru, Christine A. Iacobuzio-Donahue

Research output: Contribution to journalArticle

Abstract

Gemcitabine is considered the standard first-line therapy for patients with advanced pancreatic cancer. More recent strategies have focused on improving the efficacy of gemcitabine by either improving the method of delivery or by combining gemcitabine with other non-cross-resistant chemotherapy agents or with small-molecule drugs. However, the clinical benefits, response rates, and duration of responses have been modest. Deoxycytidine kinase (dCK) is the rate-limiting enzyme involved in the metabolism of gemcitabine. The expression of dCK has been postulated to be correlative of gemcitabine resistance. We determined the relationship of dCK immunohistochemical protein expression and/or genetic status of dCK in a panel of human pancreatic cancer tissues and pancreatic cancer cell lines and determined the relationship of these variables to the clinical outcome of patients treated with gemcitabine. We report that dCK protein expression is expressed in the majority of pancreatic cancers analyzed (40 of 44 cases, 91%) and showed a range of labeling intensities ranging from 1 + (labeling weaker in intensity than normal lymphocytes present in same section) to 3+ (labeling greater in intensity than normal lymphocytes present in same section). When labeling intensity was compared with survival, low dCK expression (1 + labeling) was correlated with both overall survival (P <0.009) and progression-free survival following gemcitabine treatment (P <0.04). Low dCK labeling intensity was also significantly correlated with patient age (70.3 ± 8.1 versus 59.8 ± 7.4 years; P <0.0006), suggesting that age-related methylation of the dCK gene may account in part for the observed differences. Sequencing of the entire dCK coding sequence in 17 cell lines and 9 patients' cancer tissues with disease progression while on gemcitabine did not identify any mutations, suggesting that genetic alterations of dCK are not a common mechanism of resistance to gemcitabine for this tumor type. Moreover, dCK labeling showed similar patterns and intensities of labeling among matched pretreatment and post-treatment tissues. In summary, pretreatment levels of dCK protein are most correlated with overall survival following gemcitabine treatment and are stable even after resistance to gemcitabine is clinically documented.

Original languageEnglish (US)
Pages (from-to)2492-2497
Number of pages6
JournalClinical Cancer Research
Volume12
Issue number8
DOIs
StatePublished - Apr 15 2006

Fingerprint

gemcitabine
Deoxycytidine Kinase
Pancreatic Neoplasms
Survival
Lymphocytes
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer : Relationship to molecular mechanisms of gemcitabine resistance and survival. / Sebastiani, Valeria; Ricci, Francesca; Rubio-Viquiera, Belen; Kulesza, Piotr; Yeo, Charles J.; Hidalgo, Manuel; Klein, Alison; Laheru, Daniel; Iacobuzio-Donahue, Christine A.

In: Clinical Cancer Research, Vol. 12, No. 8, 15.04.2006, p. 2492-2497.

Research output: Contribution to journalArticle

Sebastiani, Valeria ; Ricci, Francesca ; Rubio-Viquiera, Belen ; Kulesza, Piotr ; Yeo, Charles J. ; Hidalgo, Manuel ; Klein, Alison ; Laheru, Daniel ; Iacobuzio-Donahue, Christine A. / Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer : Relationship to molecular mechanisms of gemcitabine resistance and survival. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 8. pp. 2492-2497.
@article{f4058c230ea3441ba0d6881913659e16,
title = "Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival",
abstract = "Gemcitabine is considered the standard first-line therapy for patients with advanced pancreatic cancer. More recent strategies have focused on improving the efficacy of gemcitabine by either improving the method of delivery or by combining gemcitabine with other non-cross-resistant chemotherapy agents or with small-molecule drugs. However, the clinical benefits, response rates, and duration of responses have been modest. Deoxycytidine kinase (dCK) is the rate-limiting enzyme involved in the metabolism of gemcitabine. The expression of dCK has been postulated to be correlative of gemcitabine resistance. We determined the relationship of dCK immunohistochemical protein expression and/or genetic status of dCK in a panel of human pancreatic cancer tissues and pancreatic cancer cell lines and determined the relationship of these variables to the clinical outcome of patients treated with gemcitabine. We report that dCK protein expression is expressed in the majority of pancreatic cancers analyzed (40 of 44 cases, 91{\%}) and showed a range of labeling intensities ranging from 1 + (labeling weaker in intensity than normal lymphocytes present in same section) to 3+ (labeling greater in intensity than normal lymphocytes present in same section). When labeling intensity was compared with survival, low dCK expression (1 + labeling) was correlated with both overall survival (P <0.009) and progression-free survival following gemcitabine treatment (P <0.04). Low dCK labeling intensity was also significantly correlated with patient age (70.3 ± 8.1 versus 59.8 ± 7.4 years; P <0.0006), suggesting that age-related methylation of the dCK gene may account in part for the observed differences. Sequencing of the entire dCK coding sequence in 17 cell lines and 9 patients' cancer tissues with disease progression while on gemcitabine did not identify any mutations, suggesting that genetic alterations of dCK are not a common mechanism of resistance to gemcitabine for this tumor type. Moreover, dCK labeling showed similar patterns and intensities of labeling among matched pretreatment and post-treatment tissues. In summary, pretreatment levels of dCK protein are most correlated with overall survival following gemcitabine treatment and are stable even after resistance to gemcitabine is clinically documented.",
author = "Valeria Sebastiani and Francesca Ricci and Belen Rubio-Viquiera and Piotr Kulesza and Yeo, {Charles J.} and Manuel Hidalgo and Alison Klein and Daniel Laheru and Iacobuzio-Donahue, {Christine A.}",
year = "2006",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-05-2655",
language = "English (US)",
volume = "12",
pages = "2492--2497",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer

T2 - Relationship to molecular mechanisms of gemcitabine resistance and survival

AU - Sebastiani, Valeria

AU - Ricci, Francesca

AU - Rubio-Viquiera, Belen

AU - Kulesza, Piotr

AU - Yeo, Charles J.

AU - Hidalgo, Manuel

AU - Klein, Alison

AU - Laheru, Daniel

AU - Iacobuzio-Donahue, Christine A.

PY - 2006/4/15

Y1 - 2006/4/15

N2 - Gemcitabine is considered the standard first-line therapy for patients with advanced pancreatic cancer. More recent strategies have focused on improving the efficacy of gemcitabine by either improving the method of delivery or by combining gemcitabine with other non-cross-resistant chemotherapy agents or with small-molecule drugs. However, the clinical benefits, response rates, and duration of responses have been modest. Deoxycytidine kinase (dCK) is the rate-limiting enzyme involved in the metabolism of gemcitabine. The expression of dCK has been postulated to be correlative of gemcitabine resistance. We determined the relationship of dCK immunohistochemical protein expression and/or genetic status of dCK in a panel of human pancreatic cancer tissues and pancreatic cancer cell lines and determined the relationship of these variables to the clinical outcome of patients treated with gemcitabine. We report that dCK protein expression is expressed in the majority of pancreatic cancers analyzed (40 of 44 cases, 91%) and showed a range of labeling intensities ranging from 1 + (labeling weaker in intensity than normal lymphocytes present in same section) to 3+ (labeling greater in intensity than normal lymphocytes present in same section). When labeling intensity was compared with survival, low dCK expression (1 + labeling) was correlated with both overall survival (P <0.009) and progression-free survival following gemcitabine treatment (P <0.04). Low dCK labeling intensity was also significantly correlated with patient age (70.3 ± 8.1 versus 59.8 ± 7.4 years; P <0.0006), suggesting that age-related methylation of the dCK gene may account in part for the observed differences. Sequencing of the entire dCK coding sequence in 17 cell lines and 9 patients' cancer tissues with disease progression while on gemcitabine did not identify any mutations, suggesting that genetic alterations of dCK are not a common mechanism of resistance to gemcitabine for this tumor type. Moreover, dCK labeling showed similar patterns and intensities of labeling among matched pretreatment and post-treatment tissues. In summary, pretreatment levels of dCK protein are most correlated with overall survival following gemcitabine treatment and are stable even after resistance to gemcitabine is clinically documented.

AB - Gemcitabine is considered the standard first-line therapy for patients with advanced pancreatic cancer. More recent strategies have focused on improving the efficacy of gemcitabine by either improving the method of delivery or by combining gemcitabine with other non-cross-resistant chemotherapy agents or with small-molecule drugs. However, the clinical benefits, response rates, and duration of responses have been modest. Deoxycytidine kinase (dCK) is the rate-limiting enzyme involved in the metabolism of gemcitabine. The expression of dCK has been postulated to be correlative of gemcitabine resistance. We determined the relationship of dCK immunohistochemical protein expression and/or genetic status of dCK in a panel of human pancreatic cancer tissues and pancreatic cancer cell lines and determined the relationship of these variables to the clinical outcome of patients treated with gemcitabine. We report that dCK protein expression is expressed in the majority of pancreatic cancers analyzed (40 of 44 cases, 91%) and showed a range of labeling intensities ranging from 1 + (labeling weaker in intensity than normal lymphocytes present in same section) to 3+ (labeling greater in intensity than normal lymphocytes present in same section). When labeling intensity was compared with survival, low dCK expression (1 + labeling) was correlated with both overall survival (P <0.009) and progression-free survival following gemcitabine treatment (P <0.04). Low dCK labeling intensity was also significantly correlated with patient age (70.3 ± 8.1 versus 59.8 ± 7.4 years; P <0.0006), suggesting that age-related methylation of the dCK gene may account in part for the observed differences. Sequencing of the entire dCK coding sequence in 17 cell lines and 9 patients' cancer tissues with disease progression while on gemcitabine did not identify any mutations, suggesting that genetic alterations of dCK are not a common mechanism of resistance to gemcitabine for this tumor type. Moreover, dCK labeling showed similar patterns and intensities of labeling among matched pretreatment and post-treatment tissues. In summary, pretreatment levels of dCK protein are most correlated with overall survival following gemcitabine treatment and are stable even after resistance to gemcitabine is clinically documented.

UR - http://www.scopus.com/inward/record.url?scp=33646407273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646407273&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-2655

DO - 10.1158/1078-0432.CCR-05-2655

M3 - Article

C2 - 16638857

AN - SCOPUS:33646407273

VL - 12

SP - 2492

EP - 2497

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -